ArticleNeuro-oncology2025

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.

Alberto Delaidelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.